Table 3.
Cross-reactivity analysis for the Abbott anti-SARS-CoV-2 assay.
| N | Negative | Positive | Median (IQR) | |
|---|---|---|---|---|
| Recent influenza vaccination | 229 | 227 | 2 | 0.03 (0.02–0.05) |
| Dengue fever | 46 | 46 | 0 | 0.02 (0.02–0.04) |
| Anti-HCV | 4 | 4 | 0 | 0.04 (0.03–0.06) |
| Hepatitis B* | 29 | 29 | 0 | 0.04 (0.03–0.06) |
| Syphilis antibodies | 1 | 1 | 0 | 0.16 (NA) |
| Anti-nuclear antibodies | 11 | 11 | 0 | 0.03 (0.02–0.04) |
| Anti-dsDNA | 1 | 1 | 0 | 0.03 (NA) |
| RF positive | 5 | 5 | 0 | 0.02 (0.02–0.04) |
| Total | 326 | 324 | 2 | 0.03 (0.02–0.05) |
*
Hepatitis B cases includes various combinations of HBsAg, anti-HBc IgM, HBeAg and anti-HBe.